期刊
THROMBOSIS RESEARCH
卷 135, 期 -, 页码 S12-S15出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0049-3848(15)50433-7
关键词
Venous thromboembolism; Gender; Cancer; Anticoagulant drugs; Recurrence; Hemorrhage; Mortality
资金
- Sanofi Spain
- Bayer Pharma AG
Background: The outcome of cancer patients with acute venous thromboembolism (VTE) may differ according to gender. Methods: We used the RIETE database to compare the rate of VTE (pulmonary embolism [PE] or deep vein thrombosis [DVT]) recurrences), major bleeding and mortality during the course of anticoagulation, according to gender. Results: As of August 2014, 11,055 patients with active cancer were enrolled in RIETE, of whom 5,104 (46%) were women. During the course of anticoagulation (mean: 142 days), 505 patients developed recurrent VTE, 429 bled and 2730 died. Compared with men, women had a significantly lower rate of fatal bleeding (risk ratio [RR]: 0.69; 95% CI: 0.47-0.99) and death (RR: 0.90; 95% CI: 0.83-0.97), and a non-significantly lower rate of PE recurrences (RR 0.83; 95% CI: 0.65-1.06) and major bleeding (RR: 0.89; 95% CI: 0.74-1.08). Conclusions: During the course of anticoagulation, cancer women with VTE had a better outcome than men. (C) 2015 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据